Please assess the completion status of the following clinical trial:

Trial Title: Sipuleucel-T as Neoadjuvant Treatment in Prostate Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Adenocarcinoma of the prostate.~* Subject is scheduled for RP as the initial therapy for localized prostate cancer.~* Subject is ≥ 18 years of age.~* Subject has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.~* Subject has adequate hematologic, renal, and liver function.~Exclusion Criteria:~* Subject has any evidence of metastasis.~* Subject received hormones, including luteinizing hormone-releasing hormone agonists, antiandrogens, or 5 α-reductase inhibitors at any time prior to study screening.~* Subject has received prior radiation therapy or chemotherapy for prostate cancer.~* Subject has received systemic steroid therapy within 14 days.~* Subject has a history of stage III or greater cancer, excluding prostate cancer.~* Subjects with a history of basal or squamous cell skin cancers are allowed, provided that the subject was adequately treated and is disease-free at the time of study screening.~* Subjects with a history of stage I or II cancer must have been adequately treated and been disease-free for ≥ 3 years prior to study screening.

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Sipuleucel-T with Booster (Type: EXPERIMENTAL): Subjects were to receive 3 infusions of sipuleucel-T 12 weeks prior to RP, and then an additional booster infusion 13 weeks following RP.
- Sipuleucel-T without Booster (Type: EXPERIMENTAL): Subjects were to receive 3 infusions of sipuleucel-T 12 weeks prior to RP, with no further sipuleucel-T treatment.

Based on this trial design, predict the completion outcome and termination type (if applicable).